Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
- Author
- Kanwal Raghav MD MBBS, Rachel Riechelmann MD PhD
- Published
- Thu 21 Oct 2021
- Episode Link
- https://oncologypodcast.simplecast.com/episodes/dosing-in-later-line-crc-tx-xpfGlqAl
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
- Individualizing therapy
- Clinical data and experience informing optimal dosing
- Key adverse events
Presenters:
Kanwal Raghav, MD, MBBS
Associate Professor, Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Rachel Riechelmann, MD, PhD
Head, Clinical Oncology Department
Medical Oncologist
AC Camargo Cancer Center
Sao Paulo, Brazil
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Link to full program:
https://bit.ly/3aVXplL
